These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 22926591

  • 1. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M.
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [Abstract] [Full Text] [Related]

  • 2. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
    Lu ML, Chen TT, Kuo PH, Hsu CC, Chen CH.
    Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
    [Abstract] [Full Text] [Related]

  • 3. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.
    Silver H, Shmugliakov N.
    J Clin Psychopharmacol; 1998 Jun; 18(3):208-11. PubMed ID: 9617979
    [Abstract] [Full Text] [Related]

  • 4. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia.
    Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May 15; 32(4):1072-3. PubMed ID: 18262707
    [No Abstract] [Full Text] [Related]

  • 5. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H, Sugita T, Higuchi H, Shimizu T.
    Hum Psychopharmacol; 2002 Mar 15; 17(2):95-8. PubMed ID: 12404698
    [Abstract] [Full Text] [Related]

  • 6. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H.
    Eur Neuropsychopharmacol; 2019 Mar 15; 29(3):397-404. PubMed ID: 30595354
    [Abstract] [Full Text] [Related]

  • 7. Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials.
    Zheng W, Xiang YQ, Cai DB, Yang XH, Zhang L, Zheng W, Lu XB, Tong YM, Huang X, Ungvari GS, Sim K, Ning YP, Xiang YT.
    J Clin Psychopharmacol; 2020 Mar 15; 40(4):386-390. PubMed ID: 32618683
    [Abstract] [Full Text] [Related]

  • 8. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR.
    Biol Psychiatry; 2011 Mar 01; 69(5):442-9. PubMed ID: 21145041
    [Abstract] [Full Text] [Related]

  • 9. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.
    J Clin Psychiatry; 2003 Jun 01; 64(6):640-7. PubMed ID: 12823077
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial.
    Haji Seyed Javadi A, Shafikhani AA, Zamir SM, Khanshir ZF.
    J Clin Psychopharmacol; 2018 Apr 01; 38(2):119-124. PubMed ID: 29432331
    [Abstract] [Full Text] [Related]

  • 11. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec 01; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 12. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
    Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B.
    Am J Psychiatry; 1999 May 01; 156(5):756-60. PubMed ID: 10327910
    [Abstract] [Full Text] [Related]

  • 13. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ, Lee JG, Kim YH.
    J Psychopharmacol; 2007 Jun 01; 21(4):421-7. PubMed ID: 17092979
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M.
    Schizophr Bull; 2019 Mar 07; 45(2):350-359. PubMed ID: 29718385
    [Abstract] [Full Text] [Related]

  • 15. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.
    Am J Psychiatry; 2007 Oct 07; 164(10):1593-602. PubMed ID: 17898352
    [Abstract] [Full Text] [Related]

  • 16. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S.
    Schizophr Res; 2009 Feb 07; 107(2-3):206-12. PubMed ID: 18789844
    [Abstract] [Full Text] [Related]

  • 17. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial.
    Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K.
    Psychiatry Res; 2010 Aug 30; 179(1):19-23. PubMed ID: 20472299
    [Abstract] [Full Text] [Related]

  • 18. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS.
    J Clin Psychiatry; 2010 Nov 30; 71(11):1475-81. PubMed ID: 20816042
    [Abstract] [Full Text] [Related]

  • 19. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
    Chaichan W.
    Psychiatry Clin Neurosci; 2004 Aug 30; 58(4):364-8. PubMed ID: 15298648
    [Abstract] [Full Text] [Related]

  • 20. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
    Veerman SR, Schulte PF, Smith JD, de Haan L.
    Psychol Med; 2016 Jul 30; 46(9):1909-21. PubMed ID: 27048954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.